Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma by Padfield, Emily et al.
                          Padfield, E., Ellis, H. P., & Kurian, K. M. (2015). Current Therapeutic
Advances Targeting EGFR and EGFRvIII in Glioblastoma. Frontiers in
Oncology, 5, [5]. DOI: 10.3389/fonc.2015.00005
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.3389/fonc.2015.00005
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Frontiers Media at
http://journal.frontiersin.org/article/10.3389/fonc.2015.00005/full. Please refer to any applicable terms of use of
the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms.html
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MINI REVIEW ARTICLE
published: 29 January 2015
doi: 10.3389/fonc.2015.00005
Current therapeutic advances targeting EGFR and EGFRvIII
in glioblastoma
Emily Padfield 1, Hayley P. Ellis2* and Kathreena M. Kurian2
1 University of Bristol, Bristol, UK
2 Brain Tumour Research Group, Institute of Clinical Neurosciences, University of Bristol, Bristol, UK
Edited by:
Kerrie Leanne McDonald, University
of NSW, Australia
Reviewed by:
Keith Giles,Western Australian
Institute for Medical Research,
Australia
Terrance Johns, Monash University,
Australia
*Correspondence:
Hayley P. Ellis, Brain Tumour Research
Group, Institute of Clinical Sciences,
Southmead Hospital, University of
Bristol, Level 1, Learning and
Research Building, Bristol BS10
5NB, UK
e-mail: he1519@bristol.ac.uk
Epidermal growth factor receptor (EGFR) and EGFRvIII analysis is of current interest in
glioblastoma – the most common malignant primary CNS tumor, because of new EGFRvIII
vaccine trials underway. EGFR activation in glioblastoma promotes cellular proliferation via
activation of MAPK and PI3K–Akt pathways, and EGFRvIII is the most common variant,
leading to constitutively active EGFR. This review explains EGFR and EGFRvIII signaling in
GBM; describes targeted therapy approaches to date including tyrosine kinase inhibitor,
antibody-based therapies, vaccines and pre-clinical RNA-based therapies, and discusses
the difficulties encountered with these approaches including pathway redundancy and
intratumoral heterogeneity.
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INTRODUCTION
There is an urgent need for new molecular targeted therapies
for newly diagnosed GBM (1–4). Recent data from The Cancer
Genome Atlas project has proposed various subtypes of GBM,
each with distinct molecular properties and genetic aberrations
(5), although there is increasing recognition that there is molecu-
lar heterogeneity within individual tumors (6–8). Primary GBM
is frequently associated with epidermal growth factor receptor
(EGFR) amplifications compared with secondary GBM, which
may arise from lower grade precursors (5, 9).
Overall, aberrant amplification, deletion, or mutation of at
least one receptor tyrosine kinase (RTK) has been found in
67.3% of GBM, with EGFR accounting for 57.4% (10) (as
shown in Figure 1). In addition, around 50% of patients with
EGFR amplification harbor a specific mutation – known as
EGFRvIII – which results from an in-frame deletion of exons 2–7
(11, 12). EGFRvIII can also be present independently of EGFR
amplification (13).
Due to the frequency of EGFR aberrations, many EGFR-
targeted therapies are in development or clinical trials (14).
Although EGFR kinase inhibitor therapy has shown initial success
in other cancers such non-small cell lung cancer (15), previous tri-
als in glioblastoma have been unsuccessful to date (16–18). More
recently, interest has focused on an anti-EGFRvIII vaccine (known
as rindopepimut), which has entered clinical trials (19).
EGFR SIGNALING IN GBM
Epidermal growth factor receptor signaling has an important
role in many cancers, as cellular proliferation is mainly con-
trolled by growth factors and their receptors (Figure 1). EGFR
(also known as HER1 or ERBB1) is a receptor belonging to
the ERBB family of the RTKs (20). Ligand-binding by EGF
results in the activation of the RTK/RAS/PI(3)K pathway (21)
via receptor phosphorylation, ultimately resulting in cellular
proliferation, angiogenesis, and increased local tissue invasion as
well as resistance to apoptosis (21–23).
Ligand-binding to RTKs simultaneously activates PI3K (see
Figure 1) (22). PI3K phosphorylates phosphatidylinositol 4,5-
biphosphate (PIP2) to phosphatidylinositol 3,4,5-triphosphate
(PIP3), which results in further activation of AKT (22). AKT then
promotes activation of mTOR – a protein, which exists as two
complexes; mTORC1 and mTORC2 (24). Activation of mTORC1
promotes cellular growth by biosynthesis of proteins, lipids, and
organelles in addition to inhibition of catabolic activity (22).
mTORC2 activation results in phosphorylation and subsequent
activation of several molecules (including AKT) that are involved
in cell survival, metabolism, and proliferation (22). PTEN is a
major inhibitor of this pathway by preventing phosphorylation
of PIP2 to PIP3 (22). Loss of PTEN, such as the homozygous
deletions observed in around 36% of gliomas, results in dramatic
up-regulation of this pathway, and may be a major source of
resistance to EGFR therapies (5, 22, 23).
In vitro studies suggest that the signaling mechanism of
EGFRvIII cells can confer resistance to EGFR inhibitors (25),
because EGFRvIII signals via an mTOR2 pathway whereas
wtEGFR uses mTOR1 (24).
EGFRvIII SIGNALING
EGFRvIII is often co-expressed with wtEGFR, typically in tumors
with EGFR over-expression, which complicates our understand-
ing of its contribution to tumorigenesis (13, 26, 27). It has been
suggested that the transformation happens intracellularly, with
EGFRvIII being phosphorylated in an EGFR-dependent manner
leading to increased downstream STAT signaling (27). There is
also evidence in GBM of EGFRvIII internalization to form an
oncogenic complex with STAT3 (27).
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FIGURE 1 | EGFR signaling and targeted therapies. There are three key
signaling pathways in GBM. The RTK/RAS/PI(3)K pathway is involved in cell
growth, apoptosis resistance, invasion, and migration (pictured above with
targeted therapies). The other critically important pathways that regulate
cell proliferation and survival are p53 and RB signaling (5) [adapted from
Ref. (14)].
A retrospective analysis of clinical trials found that of 40
patients with EGFR amplification, those also expressing EGFRvIII
had significantly shorter survival (0.839 years) than patients with-
out (1.374 years), P = 0.0031 (13). Considerable growth advan-
tage has been observed in EGFRvIII transfected GBM cell lines
(U87MG.EGFRvIII), when compared to wtEGFR cell lines (28–
30). This growth advantage is thought to result from an elevated
proliferation rate coupled with a reduction in apoptosis (28). Sim-
ilar to EGFR signaling, EGFRvIII activates the RTK/RAS/PI3K
pathway as a result of EGFRvIII expression (31, 32). This results
in increased levels of phosphorylated AKT and reduced levels of
P27KIP1, a cell cycle regulator that inhibits G1–S phase transition in
cell lines (33). Furthermore, abnormal spindle-like microcephaly-
associated (ASPM) protein expression has been described in the
U87MG.EGFRvIII cells compared to parental U87MG cells (34).
ASPM promotes neural stem cell self-proliferation and hence it
has been postulated the increased expression results in enhanced
GBM progression by promoting cancer stem cell self-renewal (34).
The proliferative effects of EGFRvIII may be potentiated by
the anti-apoptotic nature of brain tissue through up-regulation of
Bcl-XL, which is a potent inhibitor of apoptosis (35). EGFRvIII
has also been shown to have a role in tumor invasiveness, for
example, in vitro studies demonstrated that U87MG.EGFRvIII
cells displayed up-regulation of genes that promote an invasive
phenotype such as matrix metalloproteinase (MMP)-13 (36). In
both scratch tests and Matrigel Invasion Chamber assays, the cells
also showed greater ability for migration and local tissue invasion
than wtEGFR cells (36).
In the presence of amplified EGFR, it has been found that reg-
ulation of the nuclear factor kappa-light-chain-enhancer of acti-
vated B cells (NF-κB) pathway through IκBαM gene transfer could
play a role in glioma angiogenesis by regulating the expression
of vascular endothelial growth factor (VEGF) and interleukin-8
(IL-8) (37).
EGFR-TARGETED THERAPIES
Four modes of targeted therapies have been used to target EGFR
including tyrosine kinase inhibitors (TKIs), antibody-based ther-
apy, immunotherapy, and pre-clinical trials of RNA therapies.
TKIs are small-molecule inhibitors, which bind to the ligand-
binding site on the extracellular domain, and are the most clinically
advanced EGFR-targeting therapy to date (14). Antibody-based
therapy uses monoclonal antibodies that correspond to the recep-
tor landscape to inhibit signaling, and can also use conjugated
antibodies that allow toxins or radioactive isotopes to be targeted
to specific cells (38). The current immunotherapy for EGFRvIII
can be administered in the form of an intradermal vaccine CDX-
110 and granulocyte macrophage-colony stimulating factor (GM-
CSF) (39). RNA therapies will also be discussed, which involve
creating antisense oligonucleotides or siRNA complementary to
the regions that it would be clinically beneficial to silence (40).
TYROSINE KINASE INHIBITORS TARGETING EGFR
Epidermal growth factor receptor TKIs gefitinib and erlotinib (see
Table 1) have been found to significantly increase progression-free
survival in non-small cell lung carcinoma (NSCLC) patients, with
one meta-analysis reporting 42.9% of patients receiving TKI ther-
apy reaching at least 1 year of progression-free survival compared
to 9.7% with chemotherapy (41). A study of gefitinib as palliative
therapy for patients with brain metastases from NSCLC found
that 45% of patients experienced symptom improvement, with
the experimental group maintaining progression-free survival for
6 months longer than the control group (42). As an initial therapy
for asymptomatic brain metastases in never-smokers with adeno-
carcinoma of the lung, the combination of gefitinib and erlotinib
has shown response rates of up to 70% (43). Lapatanib is another
tyrosine kinase inhibitor used in treatment of HER2+ breast can-
cer, which when used in combination with capecitabine was found
to increase progression-free survival to 8.4 months compared to
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Table 1 | A summary of therapies targeting EGFR and EGFRvIII.
Therapy Target Current clinical applications Problems reported in
glioma trials
Reference
Monoclonal antibodies
Cetuximab (L01XC06) EGFR/HER1 Colorectal cancer
Head and neck cancer
Panitumumab (L01XC08) EGFR/HER1 Metastatic colorectal cancer Crossing BBB
Nimotuzumab (L01XC) EGFR/HER1 Squamous cell carcinoma of head and neck Hypersensitivity (36, 46–48)
Orphan status for glioma and pancreatic cancer Nervous system toxicity
125 I-Mab 425 EGFR N/A
mAb806 EGFRvIII N/A
DAB389EGF EGFR N/A
Small molecule inhibitors
Gefitinib (L01XE02) EGFR/HER1 NSCLC
Erlotinib (L01XE03) EGFR/HER1 NSCLC and pancreatic cancer Insufficient delivery (14–17, 39–43, 49)
Lapatinib (L01XE07) EGFR/HER1/HER2 HER2+ breast cancer Resistance to inhibition
Afatinib (L01XE13) EGFR/HER1/HER2/HER4 Metastatic NSCLC
Dacomitinib EGFR/HER1/HER2/HER4 N/A
Vaccines
Rindopepimut (CDX-110) EGFRvIII N/A Tumor heterogeneity (37, 50–52)
Patient selection
4.4 months receiving capecitabine monotherapy at the primary
endpoint of a clinical trial of metastatic breast cancer patients
(44). In the monotherapy group, 11 patients had CNS metastases
compared with 4 in the combination therapy group (44), though
lapatinib has not yet been shown to have activity against recurrent
GBM in clinical trials (45).
Pre-clinical results demonstrate the ability of TKIs to inhibit
tumor cell growth, angiogenesis, survival, and proliferation in sev-
eral different EGFR transfected GBM cell lines (36, 49, 53, 54).
However, these results do not appear to be clinically translatable,
as response rates in GBM patients are disappointing for many
inhibitors including gefitinib and erlotinib (55, 56). One explana-
tion of this could be that TKIs are most efficacious when targeting
tumor cells that express mutations in exons 19 and 21 of the EGFR
kinase domain, which has been identified in various cancer types
but has not yet been elucidated in GBM (14).
ANTIBODY TARGETING OF EGFR
Despite the success of antibody-based therapy in the treatment of
renal cell carcinoma, melanoma, and hematologic cancers, these
results have not been replicated in GBM (46, 57, 58). Conjugated
and unconjugated antibodies have been developed to target both
wtEGFR and EGFRvIII, the most successful so far being cetuximab,
panitumumab, and nimotuzumab (41, 47). The unconjugated
antibodies bind the extracellular domain of EGFR, and they are
also suggested to cause internalization of EGFRvIII, though clinical
trials have had varying results (48).
Treatment of EGFR-amplified GBM cells with cetuximab in
subcutaneous and intracranial mouse xenografts has been found
to result in a significant decrease in proliferation, and an increase
in overall survival as well as apoptosis (59). A decrease in the
expression of VEGF in cell supernatant was observed using an
enzyme-linked immunosorbent assay, suggesting further potential
for application in GBM, as this signaling pathway also contributes
to tumor maintenance and angiogenesis (59).
A Phase II study stratified patients depending on their EGFR
gene amplification status and both groups were administered
cetuximab intravenously (60). Cetuximab had little effect in both
study groups and the median overall survival was 5 months, elicit-
ing no significant correlation between EGFR status and response
or overall survival (60). Other clinical trials involving similar
antibody-based therapies have been equally unsuccessful, though
a decrease in skin toxicity has been reported with use of nimo-
tuzumab, which could increase its viability as an adjuvant therapy
in GBM (47).
In a Phase III study, patients were administered nimotuzumab
with concurrent radiotherapy (47). Although there was no sta-
tistically significant difference in overall survival of patients, the
patients with the greatest median overall survival had molecular
markers of EGFR amplification and unmethylated MGMT (47).
Antibodies, which utilize toxins or radioisotopes, could provide
a potent adjuvant therapy for GBM as they enhance cell killing
by the immune system in addition to inhibition of EGFR signal-
ing (61). Various early clinical trials report that administering the
radiolabeled antibody 125I-MAb 425 intravenously, either alone
or with standard of care treatment, significantly improves median
survival (38, 50, 61). In the largest Phase II trial to date combined
treatment of 125I-mAb 425 and TMZ provided the greatest survival
benefit with a median survival of 20.4 months, compared to treat-
ment of 125I-mAb 425 alone, which was 14.5 months (50). Anti-
bodies conjugated to death receptor agonists have been reported
to induce apoptosis in GBM cell lines, for example, the scFvM58–
sTRAIL fusion, which has been shown to selectively target GBM
cells that express multidrug resistance protein 3 (62).
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IMMUNE THERAPY USING VACCINES
In initial Phase I trials, vaccinations comprising dendritic cells
(DCs) primed with EGFRvIII peptides were found to be safe, with
only grade I and II skin reactions at the vaccine injection site
reported (51). Patients were also found to be immunologically
responsive when their cellular immune responses were tested
regularly using skin tests (51). Histological analysis in recurrent
GBM patients who received the same vaccine showed no residual
expression of EGFRvIII, demonstrating that the vaccine can effec-
tively eliminate EGFRvIII cells, though all other cell types remain
intact (63).
The Phase II trial “ACTIVATE” included 19 patients with newly
diagnosed GBM received vaccines comprising PEPvIII-KLH (the
EGFRvIII peptide coupled keyhole limpet hemocyanin to illicit
both humoral and cellular immune responses) and GM-CSF (64).
Progression-free survival was 12 months and patients who demon-
strated immune sensitization to EGFRvIII had an overall survival
of 47.7 months in comparison to 22.8 months for those who did
not (64). It is important to note that positive results in these clinical
trials could be due at least in part to the use of GM-CSF, as its use
in cancer immunotherapy is enhancement of immunotherapeutic
mechanisms of tumor destruction (52).
Another arm of this trial“ACT II”compares rindopepimut/GM-
CSF concurrently with either standard or dose-intensive adjuvant
TMZ (19). All patients were found to have an immune response
to EGFRvIII; however, patients in the dose-intensive cohort had
an even greater serum response, which may be partly due to
a decrease in regulatory T cells (19). Most importantly, overall
survival was greatly improved (23.6 months) in comparison to
historical case-matched controls (19).
The larger “ACT III” trial sought to evaluate the clinical efficacy
of the peptide vaccine CDX-110 in addition to radiotherapy and
TMZ and produced similar results (65). The study was initially
a randomized Phase II/III study, but patients belonging to the
non-vaccine group withdrew from the trial (66). The median OS
was 24.6 months compared to 15.2 months for matched EGFRvIII-
positive controls (66). In addition, the results appeared to show
a benefit in patients with methylated and unmethylated MGMT
promoters (66).
A Phase III clinical trial, “ACT IV,” which compares rindo-
pepimut plus GM-CSF and TMZ to current standard of care alone
with a control (keyhole limpet hemocyanin) has been undertaken.
Screening closed for this study on 30/9/14 with around 700 patients
enrolled, and primary data collection is expected to take place in
late 2016 (NCT01480479). A further Phase II trial (ReACT) is
also underway involving patients with recurring EGFR-positive
GBM receiving the EGFRvIII vaccine in addition to bevacizumab
(NCT01498328). Also, at Stanford University a Phase I trial is
underway utilizing the EGFRvIII vaccine in children with diffuse
intrinsic pontine gliomas, as EGFR expression has been found to
occur in ~50% of the tumors studied (67).
PRE-CLINICAL AND CLINICAL TRIALS OF RNA-BASED
THERAPIES
The use of antisense oligonucleotides to inhibit translation of
mRNA has already yielded good results in pre-clinical studies for
NSCLC and prostate cancer (68, 69). Following this, several exper-
imental RNA methods targeting EGFR and EGFRvIII have been
developed, including antisense oligonucleotides, RNA interference
(RNAi), and ribozymes (40, 70, 71).
Antisense RNA appears to be efficacious in targeting EGFR
expressing cells in vitro (70, 72, 73). Injection of vectors containing
antisense RNA to target EGFRvIII into intracranial glioblastoma
xenografts were found to reduce tumor volume by>40-fold com-
pared with controls (74). In addition, in a U251 subcutaneous
mouse model treated with antisense RNA and siRNA had signifi-
cantly smaller tumor volumes by 29 and 19%, respectively, when
compared to controls, further demonstrating efficacy in vivo (40).
Therapy with siRNA leads to post-transcriptional gene silenc-
ing that results in the destruction of the target mRNA (75). siRNA
against EGFR has caused up to 90% knockdown of EGFR mRNA
in U251 glioma cells (40). These results were reproduced using
an intracranial xenograft mouse model, where median overall
survival increased by almost 90% (40).
In pre-clinical studies, ribozymes targeting EGFRvIII were
shown to inhibit ERM5–1 and U87MG glioblastoma cells (71,
76). In U87MG.EGFRvIII cells, anti-EGFRvIII hairpin ribozymes
resulted in >90% reduction of EGFRvIII mRNA and a reduction
in proliferation (71).
There may also be future potential for adjuvant miRNA-based
therapies, as miR-7 has been shown to be an efficacious inhibitor
of the EGFR signaling pathway in glioblastoma cell lines in vitro
by direct inhibition of the EGFR receptor and further independent
down-regulation of AKT, leading to a decrease in cell invasiveness
(77). An increase in the radio-sensitivity of resistant cancer cells
has also been described following miR-7 (78). The first miRNA-
based cancer therapy (MRX34) has recently entered a Phase I
clinical trial to evaluate its safety for use against primary liver can-
cer and liver metastases (NCT01829971). However, development
of miRNA-based therapies against glioma may be considerably
more difficult due to the lack of a delivery system sufficient to
bypass the blood–brain barrier (79).
LIMITATIONS OF TARGETED THERAPIES
Limitations using TKIs, such as erlotinib may have an inability
to pass the BBB due to the presence of efflux transporters on the
endothelial cells associated with the BBB (65). Additionally, at
present very little is known about the long-term adverse effects of
non-specifically inhibiting EGFR signaling using TKIs, and knowl-
edge of the biological effects of EGFR inhibitors on GBM cells is
still incomplete (14).
Drawbacks described using antibody therapy may relate to
local compared with systemic administration, for example, in
mouse models, systemic administration of an antibody directed to
EGFRvIII had no improvement in survival compared to controls,
but intratumoral injection of the antibody resulted in an increase
of median overall survival of 286% (64). A further study in rats
demonstrated that cetuximab applied by an osmotic mini-pump
significantly reduced tumor growth in the brain versus systemic
application – which failed to block tumor growth (52). This could
be due to the large molecular weight of the antibodies reduc-
ing their ability to traverse the BBB without assisted transport
vectors (80).
Cautious interpretation of the utility of the ACT IV immuno-
therapy trial is needed because patients eligible to enroll in the trial
were very highly selected, for example, they were newly diagnosed
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with complete tumor resection and no evidence of progressive
disease (NCT01480479). This is because it has been shown that in
patients with tumor resection of <95% neither over-expression of
wtEGFR nor the presence of EGFRvIII can be used independently
to predict patient survival (81). One hypothesis is that a small
tumor may still be relatively immunoprivileged; thus, the immune
system may be relatively naïve to tumor antigens (39).
In RNA studies, AAV/shRNA vectors were found to be severely
toxic, and caused fatality in 64% of mice due to oversaturation of
RNAi pathways (82, 83). Furthermore, RNA entities are anionic,
hydrophilic, and unable to enter cell by passive diffusion mech-
anisms, so the BBB is essentially impenetrable to any potentially
therapeutic RNA molecules (84).
Moreover, intratumoral heterogeneity may be a complicating
factor. A study cohort of 57 glioma cases, examining tumoral het-
erogeneity via immunohistochemistry found that in one case the
over-expression and amplification were localized to one half of the
glioma, with the other half demonstrating normal levels of EGFR
expression (85). Furthermore, not all of the samples with genetic
amplifications also had increased levels of RNA, which further
complicates the assessment of the viability of using EGFR-targeted
therapies (85).
GBM RESISTANCE TO EGFR INHIBITION
It has been previously shown that targeting of the EGFR recep-
tor can lead to selection pressure for somatic mutations at other
points in the pathway, such as inactivating phosphorylation of
PTEN, leading to resistance to EGFR inhibitors (86), which could
present a further problem for the ACT IV trial. Loss of PTEN has
previously been found to be strongly correlated with treatment
failure in GBM (87), to the extent that the analysis of EGFRvIII
and PTEN levels may be used to predict tumor response to TKI
therapy (88).
Additionally, in GBM there is a redundancy in activation of
PI3K due to the availability of several types of tyrosine kinases
upstream (86), including GFR1, MET, PDGFRα/β, and uPAR
(89, 90). Increased activation of other members of the ERBB
family of tyrosine kinases has also been described, as compen-
satory activation of ERBB2 and ERBB3 was noted after EGFR
withdrawal in GBM cancer-stem-cell lines (91). This means
that even after totally depleting EGFRvIII expressing popula-
tions of cells specifically, other tumor sub-clones with alternative
mutations could be selected for, maintaining the tumor pop-
ulation and allowing functional resistance to EGFR-targeting
therapies, and inhibitors of other ERBB family members may
also be required for down-regulation of downstream elements
(86, 91).
The loss of PTEN and increase in expression of other ERBB
receptors may render EGFR signaling dispensable in the tumor,
allowing growth and survival without EGFR signaling and thus
negating the therapeutic viability of EGFR-targeting therapies in
these cases (87, 88, 91). This uncoupling of the downstream path-
ways from EGFR signaling could be a possible explanation for the
poor clinical responses exhibited with TKIs such as erlotinib (88).
Additionally, studies examining intratumoral heterogeneity
found that it can be maintained by interactions between tumor
cells, including the up-regulation of IL-6 production in EGFRvIII
cells to activate neighboring wtEGFR cells, enhancing tumor
growth and resistance to therapy (7). The mechanisms by which
intratumoral heterogeneity arises are poorly understood; however,
tumor cells have been found to reversibly increase or decrease levels
of EGFRvIII expression in order to maximize their growth poten-
tial (92). Erlotinib resistance appears to be linked to EGFRvIII sup-
pression in extrachromosomal DNA in order to successfully evade
therapeutic mechanisms that target extrachromosomal oncogenes
(92). Surprisingly, in this study, Nathanson et al. also described a
reversal of erlotinib resistance within 72 h upon withdrawal of
the drug, where extrachromosomal EGFRvIII DNA was dramat-
ically upregulated, and restored sensitivity to TKI-induced cell
death (92).
A study comparing the efficacy of lapatinib in lung cancer and
GBM found that the lack of response to therapy in GBM could be
due to the location of the mutation. Lung cancer EGFR mutations
tend to occur in the kinase domain, whereas GBM EGFR muta-
tions are mainly in the extracellular domain, which could allow
the GBM mutant receptors sufficient flexibility within the kinase
domain to accommodate lapatinib and other type II EGFR kinase
inhibitors (93).
SUMMARY
The intratumoral heterogeneity of EGFR expression in GBM may
ultimately limit the clinical utility of therapies such as TKIs,
antibody-based therapies, and RNA-based therapies, because it
will not be possible to target every single neoplastic cell in the
tumor population. Moreover, it is likely that other sub-clones of
tumor cells will arise or other pathways may be upregulated as a
mechanism of resistance to EGFR-targeted therapies. Although
problems with EGFR intratumoral heterogeneity and pathway
redundancy will also apply to immunotherapy approaches, vac-
cines may ultimately be more attractive because they alert the
immune system to the presence of tumor and may trigger a more
non-specific tumoricidal immune response, which may potentially
eradicate all tumor cells.
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